Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02149303 · ClinicalTrials.gov registry record
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 191
- Enrollment target
NCT02149303: Completed study, sponsored by Boehringer Ingelheim.
NCT02149303 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 191 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02149303 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 191 participants
- Enrollment target
Study Summary
This study is being conducted to collect data on the management of major bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.
Primary Outcome
Proportion of subjects with index event safety outcomes (resolved / recovery ongoing / deceased) at the time of their hospital discharge / release.
Interventions
- DRUG Dabigatran 75 mg
- DRUG Dabigatran 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-03 |
What the finished NCT02149303 record still lists
NCT02149303 is an observational study that tracks outcomes without assigning an intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Dabigatran 75 mg is the first listed.
NCT02149303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02149303 about?
NCT02149303 is a clinical study titled "Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa". This study is being conducted to collect data on the management of major bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.
What is the current status of trial NCT02149303?
This trial is currently completed. The enrollment target is 191 participants. The study started on 2014-06. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02149303?
The interventions under investigation include: Dabigatran 75 mg (DRUG), Dabigatran 150 mg (DRUG).
Who is sponsoring clinical trial NCT02149303?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04621435 · 191 participants · Phase 1
Imaging of Solid Tumors Using FAP-2286
- NCT06810544 · 191 participants · Phase 1
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia